ArticleCancer science2026

NF-κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma.

Yuto Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.